Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW phase 3 trial of elritercept for transfusion-dependent anemia in lower-risk MDS
MOH_2025-04-07_013781Phase 3Not yet recruiting
- Sponsor
- Keros Therapeutics
- Start
- Mar 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Elritercept with Placebo (2 arms). Primary endpoint: Reduction in red blood cell transfusions. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2025-04-07_013781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-07_013781.